Malignant hyperthermia and ECT
- PMID: 3524274
- DOI: 10.1176/ajp.143.8.1027
Malignant hyperthermia and ECT
Abstract
The malignant hyperthermia syndrome is a rare hypermetabolic state that occurs in patients after the administration of certain drugs, most frequently anesthetics and/or succinylcholine. In view of the widespread use of succinylcholine to induce muscle relaxation prior to ECT, it is important that the individual who administers succinylcholine in this setting be familiar with the syndrome and its treatment. This report reviews what is known about malignant hyperthermia and proposes a course of action when the syndrome occurs in a patient undergoing ECT or a patient with known susceptibility to malignant hyperthermia needs ECT.
Similar articles
-
Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.BMC Psychiatry. 2024 Jun 4;24(1):411. doi: 10.1186/s12888-024-05846-5. BMC Psychiatry. 2024. PMID: 38834964 Free PMC article.
-
Malignant hyperthermia during ECT.Am J Psychiatry. 1991 Apr;148(4):541-2. doi: 10.1176/ajp.148.4.541b. Am J Psychiatry. 1991. PMID: 2006702 No abstract available.
-
More on ECT and malignant hyperthermia.Am J Psychiatry. 1983 Feb;140(2):266-7. doi: 10.1176/ajp.140.2.266c. Am J Psychiatry. 1983. PMID: 6849456 No abstract available.
-
[Malignant hyperthermia].Tunis Med. 2002 Jul;80(7):395-401. Tunis Med. 2002. PMID: 12611349 Review. French.
-
[Malignant hyperthermia].Ugeskr Laeger. 2003 Apr 21;165(17):1763-8. Ugeskr Laeger. 2003. PMID: 12768904 Review. Danish.
Cited by
-
Anesthetic management of electroconvulsive therapy in a patient with a known history of neuroleptic malignant syndrome.J Anesth. 2007;21(4):527-8. doi: 10.1007/s00540-007-0546-6. Epub 2007 Nov 1. J Anesth. 2007. PMID: 18008129 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources